MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 12-03-2025
HealthEquity Revenue 2011-2026 | HQY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue HealthEquity
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 262 M | 249 M | 216 M | 734 M | 532 M | 287 M | 230 M | 178 M | 127 M | 87.9 M | 62 M | 46.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 734 M | 46.1 M | 251 M |
Quarterly Revenue HealthEquity
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 322 M | 326 M | 331 M | - | 300 M | 300 M | 288 M | - | 249 M | 244 M | 244 M | - | 216 M | 206 M | 206 M | - | 180 M | 189 M | 184 M | 201 M | 179 M | 176 M | 190 M | 75.8 M | 157 M | 86.6 M | 87.1 M | 60.4 M | 70.5 M | 71.1 M | 69.9 M | 46.8 M | 56.8 M | 56.9 M | 55.4 M | 35.9 M | 43.4 M | 44.2 M | 44 M | 24.9 M | 30.6 M | 30.5 M | 29.8 M | 17.2 M | 21.9 M | 20.9 M | 20.2 M | - | 15.2 M | 15 M | 14.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 331 M | 14.6 M | 127 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B |  USA |
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B | USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Progyny
PGNY
|
298 M | $ 25.68 | -0.62 % | $ 2.2 B | USA |
 |
Premier
PINC
|
263 M | $ 28.26 | - | $ 2.33 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Evolent Health
EVH
|
382 M | $ 4.0 | -1.23 % | $ 375 M | USA |
 |
Health Catalyst
HCAT
|
307 M | $ 2.39 | 0.42 % | $ 144 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 23.07 | -0.86 % | $ 701 M | USA |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
10x Genomics
TXG
|
619 M | $ 16.31 | 0.12 % | $ 1.91 B | USA |
 |
MTBC
MTBC
|
111 M | - | -0.58 % | $ 51.7 M | USA |
 |
American Well Corporation
AMWL
|
254 M | $ 4.91 | 2.29 % | $ 73.6 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 12.26 | -1.05 % | $ 210 M | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.71 | 0.74 % | $ 1.05 B | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 45.3 | -1.35 % | $ 2.09 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.56 | 1.59 % | $ 203 M |  China |
 |
Phreesia
PHR
|
356 M | $ 16.92 | -0.65 % | $ 923 M | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
Schrödinger
SDGR
|
208 M | $ 17.88 | 0.45 % | $ 1.3 B | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 0.45 | -26.63 % | $ 2.34 M | China |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
2.57 B | $ 7.0 | - | $ 1.19 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
2.36 B | $ 223.23 | -0.63 % | $ 35.8 B | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.19 | -5.66 % | $ 277 K | USA |